Skip to main content

Table 2 Pooled MD/RR and relative CrI derived from three-node network meta-analysis with different treatment regimens in migraine patients with previous preventive treatment failures

From: Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis

Intervention

MD/RR (95% CrI) estimates derived from NMA

SUCRA

CGRP mAbs vs. placebo

CGRP receptor mAbs vs. placebo

CGRP mAbs vs. CGRP receptor mAbs

CGRP mAbs

CGRP receptor mAbs

Placebo

Efficacy outcomes

 Change in MMDs

-3.29 (−3.97, −2.76)

-1.74 (−2.72, −1.11)

-1.55 (−2.43, −0.44)

0.99

0.50

0.01

 50% response rates

3.66 (3.01, 4.49)

2.40 (1.76, 3.35)

1.52 (1.04, 2.21)

0.99

0.51

0.01

 75% response rates

6.29 (4.07, 10.29)

5.38 (2.58, 13.21)

1.17 (0.43, 2.86)

0.81

0.69

0.01

Safety outcomes

 TEAEs

0.99 (0.88, 1.12)

0.99 (0.87, 1.13)

1.00 (0.84, 1.19)

0.55

0.51

0.44

 Serious adverse events

1.31 (0.58, 3.07)

2.24 (0.58, 11.20)

0.58 (0.10, 2.83)

0.50

0.19

0.81

  1. CrI Credibility interval; CGRP Calcitonin gene-related peptide; mAbs Monoclonal antibodies; MD Mean difference; MMDs Monthly migraine days; NMA Network meta-analysis; RR Relative risk; SUCRA Surface under the cumulative ranking curve; TEAEs Treatment­emergent adverse events